Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
$11.52
$11.50
$5.57
$11.98
$397.94M1.11106,940 shs9,831 shs
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$6.61
-1.0%
$5.37
$3.21
$7.18
$1.59B0.733.12 million shs2.35 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.31
-1.2%
$30.52
$24.07
$55.33
$1.53B2.311.30 million shs1.50 million shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$23.77
-3.1%
$22.28
$18.53
$51.61
$1.52B1.171.84 million shs1.08 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
0.00%0.00%0.00%0.00%0.00%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.00%+1.38%+10.72%+80.60%+4.75%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-1.75%-9.99%-27.77%-46.09%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.00%-1.74%+10.35%+8.79%-36.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
$11.52
$11.50
$5.57
$11.98
$397.94M1.11106,940 shs9,831 shs
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$6.61
-1.0%
$5.37
$3.21
$7.18
$1.59B0.733.12 million shs2.35 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.31
-1.2%
$30.52
$24.07
$55.33
$1.53B2.311.30 million shs1.50 million shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$23.77
-3.1%
$22.28
$18.53
$51.61
$1.52B1.171.84 million shs1.08 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
0.00%0.00%0.00%0.00%0.00%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.00%+1.38%+10.72%+80.60%+4.75%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-1.75%-9.99%-27.77%-46.09%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.00%-1.74%+10.35%+8.79%-36.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
0.00
N/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.10
Buy$11.7077.00% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4095.18% Upside
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
2.90
Moderate Buy$63.00165.04% Upside

Current Analyst Ratings Breakdown

Latest ARA, ARDX, TWST, and VERA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageStrong-Buy$14.00
9/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperformStrong-Buy
8/7/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$56.00 ➝ $53.00
8/6/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$8.00 ➝ $9.00
8/5/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$12.00
8/5/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$11.00 ➝ $12.00
8/5/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$13.00 ➝ $14.00
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$46.00
8/4/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformPeer Perform
6/18/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$10.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
$822.52M0.48$1.69 per share6.80$2.59 per share4.45
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M4.77N/AN/A$0.73 per share9.05
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M4.88N/AN/A$8.07 per share3.14
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/A$9.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
-$13.79M$0.26N/AN/AN/A-2.04%-3.56%-0.24%N/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.23N/A21.32N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)

Latest ARA, ARDX, TWST, and VERA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$0.82-$1.20-$0.38-$1.20N/AN/A
8/4/2025Q2 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
N/AN/AN/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
7.54
1.05
1.02
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.44
4.30
4.03
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.16
17.03
17.03

Institutional Ownership

CompanyInstitutional Ownership
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
78.42%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
99.21%

Insider Ownership

CompanyInsider Ownership
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
9.50%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
16.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
4,97734.54 millionN/AOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90240.98 million229.42 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
4063.82 million53.42 millionOptionable

Recent News About These Companies

Vera Therapeutics (VERA) Stock Surges 27% Over Last Month

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
American Renal Associates stock logo

American Renal Associates NYSE:ARA

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$6.61 -0.07 (-1.05%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$6.60 -0.02 (-0.23%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$25.31 -0.30 (-1.17%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$25.54 +0.24 (+0.93%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vera Therapeutics stock logo

Vera Therapeutics NASDAQ:VERA

$23.77 -0.76 (-3.10%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$23.54 -0.23 (-0.97%)
As of 04:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.